ScinoPharm Taiwan Ltd
TWSE:1789
Balance Sheet
Balance Sheet Decomposition
ScinoPharm Taiwan Ltd
ScinoPharm Taiwan Ltd
Balance Sheet
ScinoPharm Taiwan Ltd
| Dec-2007 | Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||
| Cash & Cash Equivalents |
247
|
590
|
740
|
1 908
|
3 293
|
3 035
|
2 289
|
1 928
|
2 336
|
3 707
|
3 911
|
4 203
|
3 305
|
4 055
|
4 081
|
4 295
|
3 942
|
4 166
|
|
| Cash |
0
|
0
|
0
|
0
|
206
|
473
|
456
|
565
|
472
|
517
|
288
|
290
|
415
|
232
|
186
|
146
|
153
|
167
|
|
| Cash Equivalents |
247
|
590
|
740
|
1 908
|
3 087
|
2 562
|
1 833
|
1 362
|
1 864
|
3 190
|
3 623
|
3 913
|
2 890
|
3 823
|
3 895
|
4 148
|
3 789
|
3 999
|
|
| Short-Term Investments |
4
|
5
|
46
|
11
|
16
|
0
|
16
|
0
|
284
|
0
|
0
|
179
|
172
|
34
|
51
|
51
|
0
|
0
|
|
| Total Receivables |
562
|
382
|
918
|
753
|
892
|
938
|
1 132
|
722
|
1 075
|
836
|
765
|
663
|
670
|
473
|
393
|
654
|
813
|
654
|
|
| Accounts Receivables |
537
|
366
|
891
|
731
|
844
|
841
|
971
|
523
|
867
|
638
|
567
|
559
|
590
|
387
|
360
|
635
|
788
|
634
|
|
| Other Receivables |
25
|
16
|
27
|
22
|
48
|
97
|
161
|
199
|
208
|
198
|
198
|
104
|
80
|
86
|
33
|
18
|
25
|
21
|
|
| Inventory |
1 128
|
1 246
|
948
|
1 244
|
1 465
|
1 870
|
2 512
|
2 449
|
2 169
|
1 830
|
1 675
|
1 364
|
1 124
|
1 246
|
1 345
|
1 189
|
1 512
|
1 673
|
|
| Other Current Assets |
199
|
229
|
120
|
161
|
182
|
214
|
194
|
150
|
169
|
212
|
116
|
97
|
135
|
108
|
97
|
132
|
114
|
115
|
|
| Total Current Assets |
2 140
|
2 452
|
2 771
|
4 078
|
5 849
|
6 058
|
6 143
|
5 250
|
6 033
|
6 585
|
6 467
|
6 506
|
5 407
|
5 916
|
5 967
|
6 320
|
6 381
|
6 608
|
|
| PP&E Net |
3 078
|
2 831
|
2 782
|
2 812
|
3 237
|
3 797
|
4 613
|
5 350
|
5 329
|
5 274
|
5 199
|
4 868
|
5 192
|
4 975
|
4 883
|
4 797
|
4 578
|
4 576
|
|
| PP&E Gross |
3 078
|
2 831
|
2 782
|
2 812
|
3 237
|
3 797
|
4 613
|
5 350
|
5 329
|
5 274
|
5 199
|
4 868
|
5 192
|
4 975
|
4 883
|
4 797
|
4 578
|
4 576
|
|
| Accumulated Depreciation |
1 627
|
1 840
|
2 183
|
2 463
|
2 793
|
3 061
|
3 379
|
3 791
|
4 195
|
4 601
|
4 987
|
5 364
|
5 664
|
5 962
|
6 277
|
6 659
|
6 999
|
7 416
|
|
| Intangible Assets |
108
|
68
|
31
|
60
|
13
|
18
|
29
|
24
|
23
|
24
|
23
|
17
|
14
|
9
|
9
|
10
|
19
|
17
|
|
| Long-Term Investments |
115
|
210
|
18
|
241
|
196
|
207
|
283
|
272
|
364
|
393
|
420
|
497
|
444
|
337
|
215
|
144
|
101
|
101
|
|
| Other Long-Term Assets |
196
|
176
|
222
|
106
|
193
|
261
|
416
|
476
|
473
|
506
|
592
|
675
|
617
|
610
|
617
|
640
|
643
|
640
|
|
| Total Assets |
5 637
N/A
|
5 738
+2%
|
5 824
+1%
|
7 298
+25%
|
9 488
+30%
|
10 340
+9%
|
11 484
+11%
|
11 372
-1%
|
12 222
+7%
|
12 783
+5%
|
12 701
-1%
|
12 563
-1%
|
11 675
-7%
|
11 847
+1%
|
11 691
-1%
|
11 911
+2%
|
11 722
-2%
|
11 943
+2%
|
|
| Liabilities | |||||||||||||||||||
| Accounts Payable |
121
|
32
|
64
|
146
|
299
|
224
|
266
|
55
|
92
|
71
|
92
|
91
|
102
|
161
|
71
|
126
|
102
|
82
|
|
| Accrued Liabilities |
160
|
251
|
262
|
295
|
0
|
0
|
0
|
115
|
131
|
152
|
126
|
127
|
104
|
126
|
125
|
140
|
140
|
143
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
264
|
690
|
1 277
|
1 702
|
983
|
375
|
233
|
90
|
9
|
0
|
78
|
32
|
36
|
|
| Current Portion of Long-Term Debt |
10
|
105
|
297
|
2
|
0
|
0
|
0
|
0
|
0
|
32
|
220
|
1 179
|
160
|
17
|
18
|
18
|
18
|
20
|
|
| Other Current Liabilities |
42
|
45
|
60
|
153
|
558
|
716
|
819
|
470
|
350
|
454
|
303
|
317
|
285
|
374
|
343
|
442
|
438
|
487
|
|
| Total Current Liabilities |
333
|
434
|
683
|
595
|
858
|
1 204
|
1 775
|
1 918
|
2 275
|
1 692
|
1 115
|
1 946
|
742
|
687
|
556
|
803
|
729
|
768
|
|
| Long-Term Debt |
2 749
|
1 844
|
647
|
1
|
0
|
0
|
0
|
0
|
0
|
771
|
1 098
|
0
|
590
|
550
|
540
|
581
|
570
|
620
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
3
|
1
|
0
|
0
|
1
|
0
|
0
|
0
|
2
|
1
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
21
|
21
|
22
|
25
|
63
|
65
|
66
|
70
|
86
|
92
|
71
|
79
|
82
|
81
|
83
|
77
|
56
|
28
|
|
| Total Liabilities |
3 103
N/A
|
2 300
-26%
|
1 352
-41%
|
621
-54%
|
923
+49%
|
1 271
+38%
|
1 841
+45%
|
1 992
+8%
|
2 365
+19%
|
2 555
+8%
|
2 284
-11%
|
2 024
-11%
|
1 415
-30%
|
1 317
-7%
|
1 180
-10%
|
1 461
+24%
|
1 357
-7%
|
1 417
+4%
|
|
| Equity | |||||||||||||||||||
| Common Stock |
5 510
|
5 514
|
5 514
|
6 100
|
6 310
|
6 499
|
6 759
|
7 030
|
7 311
|
7 603
|
7 907
|
7 907
|
7 907
|
7 907
|
7 907
|
7 907
|
7 907
|
7 907
|
|
| Retained Earnings |
2 974
|
2 101
|
1 060
|
80
|
1 008
|
1 358
|
1 592
|
993
|
1 212
|
1 352
|
1 243
|
1 299
|
1 126
|
1 360
|
1 370
|
1 346
|
1 348
|
1 450
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
499
|
1 247
|
1 247
|
1 248
|
1 257
|
1 266
|
1 276
|
1 287
|
1 293
|
1 295
|
1 295
|
1 295
|
1 295
|
1 295
|
1 295
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
81
|
30
|
43
|
18
|
55
|
98
|
98
|
|
| Other Equity |
3
|
26
|
19
|
1
|
0
|
35
|
44
|
101
|
69
|
3
|
20
|
41
|
98
|
76
|
79
|
43
|
88
|
29
|
|
| Total Equity |
2 533
N/A
|
3 439
+36%
|
4 472
+30%
|
6 677
+49%
|
8 565
+28%
|
9 069
+6%
|
9 643
+6%
|
9 380
-3%
|
9 857
+5%
|
10 228
+4%
|
10 417
+2%
|
10 539
+1%
|
10 260
-3%
|
10 529
+3%
|
10 511
0%
|
10 450
-1%
|
10 364
-1%
|
10 526
+2%
|
|
| Total Liabilities & Equity |
5 637
N/A
|
5 738
+2%
|
5 824
+1%
|
7 298
+25%
|
9 488
+30%
|
10 340
+9%
|
11 484
+11%
|
11 372
-1%
|
12 222
+7%
|
12 783
+5%
|
12 701
-1%
|
12 563
-1%
|
11 675
-7%
|
11 847
+1%
|
11 691
-1%
|
11 911
+2%
|
11 722
-2%
|
11 943
+2%
|
|
| Shares Outstanding | |||||||||||||||||||
| Common Shares Outstanding |
764
|
764
|
764
|
764
|
791
|
791
|
791
|
791
|
791
|
760
|
791
|
791
|
791
|
791
|
791
|
791
|
791
|
791
|
|